Disease

peripheral T-cell lymphoma, not otherwise specified

Late-stage therapeutic development

Also known as PTCL.

Clinical trials

Associated genes

Related proteins

Current focus

Deacetylase hdac6 biologyTherapeutic developmentTransforming rhoa biology

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate

Key developments

5 clinical trials expected to report results, the earliest in Q3 2027.

Upcoming Milestones

Major developments

Upcoming trial readoutHigh impact

A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physician's Choice Standard of Care Treatment (Selected Single Agent) in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Results expected Q4 20272026-09-25

Upcoming trial readoutHigh impact

A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients With Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)

Results expected Q2 20282026-08-19

Clinical Milestones7View

Results posted 1

2026-08-21A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell LymphomasResults posted

Results expected 5

Other updates 1

2029-03-01Phase II Study of Brentuximab Vedotin in Combination With Pembrolizumab in Patients With Recurrent Systemic Peripheral T-Cell Lymphoma (PTCL)Withdrawn

Activity timeline7

2029-03-01ClinicalPhase II Study of Brentuximab Vedotin in Combination With Pembrolizumab in Patients With Recurrent Systemic Peripheral T-Cell Lymphoma (PTCL)Withdrawn
2026-09-25ClinicalA Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physician's Choice Standard of Care Treatment (Selected Single Agent) in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaResults expected Q4 2027
2026-08-21ClinicalA Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell LymphomasResults posted
2026-08-19ClinicalA Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients With Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)Results expected Q2 2028
2026-08-05ClinicalA Phase II Study of Duvelisib Maintenance After First-Line Therapy for Peripheral T-Cell LymphomaResults expected Q4 2027
2026-07-31ClinicalA Phase 1/2 Trial of Durvalumab (MEDI4736) When Given as a Single Agent or in Combination With Lenalidomide in Patients With Relapsed/ Refractory Peripheral T-cell Lymphoma, Including Cutaneous T-cell LymphomaResults expected Q2 2030
2026-01-09ClinicalA Phase I/II Study of Pembrolizumab (MK-3475) in Combination With Romidepsin in Patients With Relapsed or Refractory Peripheral T-Cell LymphomaResults expected Q3 2027

Clinical trials

9 sponsors · 1 new · 0 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme

All trials

Active

Late-stage

Completed

Late-stage studies

Phase 3 · Recruiting · Eastern Cooperative Oncology Group

Phase 3 · Recruiting · Corvus Pharmaceuticals, Inc.

Recruiting

Phase 3 · Recruiting · Eastern Cooperative Oncology Group

Phase 3 · Recruiting · Corvus Pharmaceuticals, Inc.

A Phase II Study of Duvelisib Maintenance After First-Line Therapy for Peripheral T-Cell Lymphoma

Phase 2 · Recruiting · City of Hope Medical Center

A Phase 1/2 Trial of Durvalumab (MEDI4736) When Given as a Single Agent or in Combination With Lenalidomide in Patients With Relapsed/ Refractory Peripheral T-cell Lymphoma, Including Cutaneous T-cell Lymphoma

Phase 1/2 · Recruiting · City of Hope Medical Center

Recently completed

Bispecific NK Engager AFM13 Combined With NK Cells for Patients With Recurrent of Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Phase 1/2 · Completed · M.D. Anderson Cancer Center

A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Phase 2 · Completed · BeiGene

A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma

Phase 1/2 · Completed · University of Nebraska

Phase I Study of Romidepsin (ISTODAX®) Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Phase 1 · Completed · M.D. Anderson Cancer Center

Associated genes

10 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

HDAC90.52 HDAC10.52 HDAC60.52 HDAC100.52 HDAC20.52 HDAC30.52 HDAC80.52 RHOA0.37 TAL10.37 STIL0.37

Disease biology

5 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Histone deacetylase 1via HDAC10.52 Protein deacetylase HDAC6via HDAC60.52 Histone deacetylase 2via HDAC20.52 Histone deacetylase 3via HDAC30.52 Transforming protein RhoAvia RHOA0.37

Reference

Authoritative identity, definition & identifiers.

Synonyms

PTCL

References & data sources

Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
Related entities are derived from literature co-mention (studied together) — associative, not causal.